AR120309A1 - Formulaciones de polvo seco de anticuerpos que se unen a la linfopoyetina del estroma tímico (tslp) y métodos de uso de las mismas - Google Patents
Formulaciones de polvo seco de anticuerpos que se unen a la linfopoyetina del estroma tímico (tslp) y métodos de uso de las mismasInfo
- Publication number
- AR120309A1 AR120309A1 ARP200102963A ARP200102963A AR120309A1 AR 120309 A1 AR120309 A1 AR 120309A1 AR P200102963 A ARP200102963 A AR P200102963A AR P200102963 A ARP200102963 A AR P200102963A AR 120309 A1 AR120309 A1 AR 120309A1
- Authority
- AR
- Argentina
- Prior art keywords
- amino acid
- seq
- set forth
- acid sequence
- sequence set
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
- A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39591—Stabilisation, fragmentation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/244—Interleukins [IL]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
- A61K2039/541—Mucosal route
- A61K2039/543—Mucosal route intranasal
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/22—Immunoglobulins specific features characterized by taxonomic origin from camelids, e.g. camel, llama or dromedary
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Pulmonology (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Otolaryngology (AREA)
- Genetics & Genomics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
Abstract
La presente tecnología se refiere, en general, a formulaciones de polvo seco de anticuerpos específicos de la linfopoyetina del estroma tímico (TSLP), así como a métodos de tratamiento del asma, usando las formulaciones de polvo seco, convenientemente, por vía pulmonar. Reivindicación 1: Una formulación de polvo seco que comprende una pluralidad de micropartículas, comprendiendo las micropartículas: a. leucina; b. de aproximadamente el 1% a aproximadamente el 10% en peso de trileucina; y c. un fragmento de unión a antígeno de un anticuerpo anti-linfopoyetina del estroma tímico (TSLP) que comprende: un dominio variable de cadena pesada que comprende: i. una secuencia de CDR1 de cadena pesada que comprende la secuencia de aminoácidos establecida en SEQ ID Nº 1; ii. una secuencia de CDR2 de cadena pesada que comprende la secuencia de aminoácidos establecida en SEQ ID Nº 2; y iii. una secuencia de CDR3 de cadena pesada que comprende la secuencia de aminoácidos establecida en SEQ ID Nº 3, en donde cualquiera de las CDR1, 2 ó 3 de cadena pesada comprende opcionalmente una sustitución de un solo aminoácido; y un dominio variable de cadena ligera que comprende: i. una secuencia de CDR1 de cadena ligera que comprende la secuencia de aminoácidos establecida en SEQ ID Nº 5; ii. una secuencia de CDR2 de cadena ligera que comprende la secuencia de aminoácidos establecida en SEQ ID Nº 6, y iii. una secuencia de CDR3 de cadena ligera que comprende la secuencia de aminoácidos establecida en SEQ ID Nº 7; en donde cualquiera de las CDR1, 2 ó 3 de cadena ligera comprende opcionalmente una sustitución de un solo aminoácido, en donde la leucina y la trileucina están presentes en una proporción de concentraciones de leucina: trileucina de aproximadamente 0.1:1 a aproximadamente 30.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962926833P | 2019-10-28 | 2019-10-28 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR120309A1 true AR120309A1 (es) | 2022-02-09 |
Family
ID=73030137
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP200102963A AR120309A1 (es) | 2019-10-28 | 2020-10-27 | Formulaciones de polvo seco de anticuerpos que se unen a la linfopoyetina del estroma tímico (tslp) y métodos de uso de las mismas |
Country Status (16)
| Country | Link |
|---|---|
| US (2) | US11904053B2 (es) |
| EP (1) | EP4051708A1 (es) |
| JP (1) | JP2022554249A (es) |
| KR (1) | KR20220088752A (es) |
| CN (1) | CN114867748A (es) |
| AR (1) | AR120309A1 (es) |
| AU (1) | AU2020376222A1 (es) |
| BR (1) | BR112022008031A2 (es) |
| CA (1) | CA3154999A1 (es) |
| CL (1) | CL2023003432A1 (es) |
| CO (1) | CO2022005391A2 (es) |
| CR (1) | CR20220189A (es) |
| IL (1) | IL292437A (es) |
| MX (1) | MX2022005083A (es) |
| TW (1) | TW202131947A (es) |
| WO (1) | WO2021083908A1 (es) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2024516962A (ja) * | 2021-04-19 | 2024-04-18 | メドイミューン・リミテッド | 安定性が改善された抗ＴＳＬＰ Ｆａｂ |
| US20230270668A1 (en) * | 2021-10-11 | 2023-08-31 | Augmenta Bioworks, Inc. | Dry formulations of anti-sars-cov-2 virus antibodies and compositions and methods of use thereof |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK1666028T3 (da) | 1999-10-29 | 2010-06-21 | Novartis Ag | Tørre pulversammensætninger med forbedret dispersitet |
| US7982016B2 (en) | 2007-09-10 | 2011-07-19 | Amgen Inc. | Antigen binding proteins capable of binding thymic stromal lymphopoietin |
| WO2016142426A1 (en) * | 2015-03-11 | 2016-09-15 | Glaxosmithkline Intellectual Property Development Limited | Tslp binding proteins |
| UY36889A (es) * | 2015-09-09 | 2017-04-28 | Novartis Ag | Moléculas de unión a linfopoyetina estromal timica (tslp) y métodos de uso de las moléculas |
| RU2731212C2 (ru) * | 2015-09-09 | 2020-08-31 | Новартис Аг | Направленная доставка высушенных распылением композиций в легкие |
| MX2018003038A (es) * | 2015-09-09 | 2018-04-11 | Novartis Ag | Moleculas de union a linfopoyetina estromal timica (tslp) y metodos de uso de las moleculas. |
| JOP20190243A1 (ar) * | 2017-04-12 | 2019-10-13 | Medimmune Llc | علاج الربو بجسم مضاد لـ tslp |
| WO2019145897A1 (en) | 2018-01-26 | 2019-08-01 | Novartis Ag | High dose delivery of inhaled therapeutics |
-
2020
- 2020-10-27 CN CN202080086052.9A patent/CN114867748A/zh active Pending
- 2020-10-27 US US17/081,821 patent/US11904053B2/en active Active
- 2020-10-27 AU AU2020376222A patent/AU2020376222A1/en active Pending
- 2020-10-27 KR KR1020227017241A patent/KR20220088752A/ko unknown
- 2020-10-27 EP EP20797753.9A patent/EP4051708A1/en active Pending
- 2020-10-27 CR CR20220189A patent/CR20220189A/es unknown
- 2020-10-27 AR ARP200102963A patent/AR120309A1/es unknown
- 2020-10-27 WO PCT/EP2020/080201 patent/WO2021083908A1/en unknown
- 2020-10-27 CA CA3154999A patent/CA3154999A1/en active Pending
- 2020-10-27 JP JP2022525006A patent/JP2022554249A/ja active Pending
- 2020-10-27 IL IL292437A patent/IL292437A/en unknown
- 2020-10-27 BR BR112022008031A patent/BR112022008031A2/pt unknown
- 2020-10-27 MX MX2022005083A patent/MX2022005083A/es unknown
- 2020-10-28 TW TW109137435A patent/TW202131947A/zh unknown
-
2022
- 2022-04-28 CO CONC2022/0005391A patent/CO2022005391A2/es unknown
- 2022-11-09 US US18/053,941 patent/US20230201120A1/en active Pending
-
2023
- 2023-11-19 CL CL2023003432A patent/CL2023003432A1/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| IL292437A (en) | 2022-06-01 |
| KR20220088752A (ko) | 2022-06-28 |
| BR112022008031A2 (pt) | 2022-07-12 |
| CO2022005391A2 (es) | 2022-08-19 |
| US20210121406A1 (en) | 2021-04-29 |
| CR20220189A (es) | 2022-08-19 |
| MX2022005083A (es) | 2022-07-19 |
| AU2020376222A1 (en) | 2022-06-02 |
| CL2023003432A1 (es) | 2024-05-17 |
| US20230201120A1 (en) | 2023-06-29 |
| EP4051708A1 (en) | 2022-09-07 |
| CA3154999A1 (en) | 2021-05-06 |
| US11904053B2 (en) | 2024-02-20 |
| WO2021083908A1 (en) | 2021-05-06 |
| JP2022554249A (ja) | 2022-12-28 |
| CN114867748A (zh) | 2022-08-05 |
| TW202131947A (zh) | 2021-09-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR099812A1 (es) | Anticuerpos y conjugados de anticuerpo y fármaco anti-egfr | |
| AR127371A2 (es) | Receptores quiméricos de flt3 y métodos para usarlos | |
| AR120309A1 (es) | Formulaciones de polvo seco de anticuerpos que se unen a la linfopoyetina del estroma tímico (tslp) y métodos de uso de las mismas | |
| CO2019007844A2 (es) | Anticuerpo anti-receptor de transferrina humana novedoso capaz de penetrar la barrera hematoencefálica | |
| AR117727A1 (es) | Anticuerpos que se unen a cd3 | |
| AR068508A1 (es) | Anticuerpo capaz de enlazar linfopoyetina estromal timica | |
| PE20181805A1 (es) | Composiciones y anticuerpos anti-tim-3 | |
| PE20190976A1 (es) | Anticuerpos de union a cd3 | |
| UY37694A (es) | Dominios de unión a antígeno humanizados y métodos de uso | |
| PE20110225A1 (es) | Composiciones y metodos para anticuerpos que se dirigen a la proteina de complemento c5 | |
| PE20140882A1 (es) | Anticuerpos neutralizantes de citomegalovirus humano | |
| PE20180927A1 (es) | Moleculas de union a lag-3 y metodos de uso de las mismas | |
| AR095980A1 (es) | Anticuerpos biespecíficos específicos para fap (proteína de activación fibroblástica) y dr5 (receptor de muerte 5), anticuerpos específicos para dr5 y métodos de utilización | |
| CL2008003004A1 (es) | Anticuerpo anti-esclerostina o su porción de enlace de antígeno; polinucleotido que lo codifica; vector; célula; proceso de producción; composición farmacéutica que lo comprende; método para identificar células y su uso para tratar trastornos óseos. | |
| AR103891A1 (es) | Proteínas de unión a tslp, ácido nucleico aislado que la codifica, vector y célula hospedadora que lo comprenden, método para producir dicha proteína, su uso para fabricar un medicamento, composición farmacéutica y kit que la comprenden | |
| PE20121702A1 (es) | Proteinas de enlace cd127 | |
| AR083747A1 (es) | Anticuerpos anti-il-23 | |
| PE20120475A1 (es) | Anticuerpos especificos para dkk-1 | |
| AR082916A1 (es) | Moleculas de union a 4-1bb | |
| AR082163A1 (es) | Anticuerpos especificamente ligantes del tslpr humano y metodos de utilizacion de los mismos | |
| AR110659A1 (es) | Proteínas de unión a antígenos anti-neuropilin y método para su uso | |
| AR085600A1 (es) | Agentes de union biespecifica | |
| AR100573A1 (es) | Anticuerpos anti-il-17, un método para producirlos y utilizarlos | |
| ES2684173T3 (es) | Anticuerpos anti-XCR1 humano | |
| Chen et al. | Characterization of germline antibody libraries from human umbilical cord blood and selection of monoclonal antibodies to viral envelope glycoproteins: implications for mechanisms of immune evasion and design of vaccine immunogens |